Leadership from the Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP) Anatomic and Clinical Pathology Residency Program are pleased to announce the selection of Justin Juskewitch, M.D., Ph.D., and Kabeer Shah, D.O., as Chief Residents for the Anatomic/Clinical Pathology Residency Program for the academic year 2017–18.
Duties of the chief residents include making conference schedules, call schedules, monthly rotation schedules, and participation as resident representatives on the DLMP Education Committee and Residency Recruitment Committee. DLMP leadership thanks Aleh (Oleg) Bobr, M.D., and Andrew Norgan, M.D, Ph.D., the current Chief Residents who have performed their leadership duties admirably and will be transitioning out of their roles in March.
About Dr. Justin Juskewitch
Dr. Juskewitch is a third-year resident with a focus on Transfusion Medicine and Informatics. He completed his medical training at the Mayo Clinic College of Medicine and Science and his graduate training at Mayo Clinic Graduate School of Biomedical Sciences. He states that one of his proudest moments as a pathology resident was being part of the multidisciplinary team involving Transfusion Medicine, Obstetrics, and Anesthesia to care for several expectant mothers in the community who had developed antibodies to their growing child’s circulating red blood cells. In one of those cases, the mother developed a red blood cell antibody, so rare that it would react to nearly all of Mayo's institutional blood donors. In each case, Mayo's blood bank and Transfusion Medicine teams facilitated the collection and special processing of multiple intrauterine blood transfusions for each mother to support her child throughout the remainder of the pregnancy. Each of those children was delivered successfully with minimal complications.
About Dr. Kabeer Shah
Dr. Shah is a third-year resident with a focus on Dermatopathology. He completed his medical training at Rocky Vista University in Colorado. While in the residency program, Dr. Shah has been involved in melanoma research and helped to identify a novel molecular pathway (ALK alternate transcription initiation) in a subset of metastatic melanoma patients. This patient cohort now has a new potential directed therapy. Recently, Dr. Shah has worked with Oncology and pharmaceutical colleagues to develop a clinical trial and companion diagnostic test.